- NASDAQ:ATOS surged a further 10.65% on Thursday outpacing the broader markets.
- Atossa received a letter from the FDA for its ovarian cancer therapy.
- Atossa also has a COVID-19 nasal spray treatment coming down the pipeline.
NASDAQ:ATOS continued its week-long run as the stock has already gained nearly 80% since Monday, and it has shown no signs of slowing down. On Thursday, shares added a further 10.65% to close the day at $3.22, after briefly touching $3.60 during intraday trading. Atossa is now trading above its 50-day and 200-day moving averages, and is firmly within reach of its 52-week high price of $5.08. Atossa recorded double the average daily trading volume on Thursday, and has seen its market cap bounce back to $230 million.
Stay up to speed with hot stocks' news!
The reason for Atossa’s recent surge is what every small-cap biotech company shareholders are waiting for: an FDA approval letter for its treatment. While the FDA letter is not explicit approval for the treatment to hit the markets, the letter does give Atossa a ‘safe to proceed’ status under its Expanded Access Pathway for oncology and infectious diseases. The treatment in question is Endoxifen, a therapy for women who suffer from ovarian cancer. If eventually approved, Endoxifen could be one of the leading therapies for ovarian cancer tumors, and is currently being tested at the University of Washington Medical Center.
ATOS Stock news
Atossa also has a potential COVID-19 treatment coming down the pipeline in the form of a nasal spray, which does have some interest considering there is a large population of people who do not like syringes. The nasal spray also has logistical benefits including not having to be shipped or stored at certain temperatures, so medical centers and doctor’s offices may prefer to keep Atossa’s treatment on hand.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD trades with negative bias, holds above 1.0700 as traders await US PCE Price Index
EUR/USD edges lower during the Asian session on Friday and moves away from a two-week high, around the 1.0740 area touched the previous day. Spot prices trade around the 1.0725-1.0720 region and remain at the mercy of the US Dollar price dynamics ahead of the crucial US data.
USD/JPY jumps above 156.00 on BoJ's steady policy
USD/JPY has come under intense buying pressure, surging past 156.00 after the Bank of Japan kept the key rate unchanged but tweaked its policy statement. The BoJ maintained its fiscal year 2024 and 2025 core inflation forecasts, disappointing the Japanese Yen buyers.
Gold price flatlines as traders look to US PCE Price Index for some meaningful impetus
Gold price lacks any firm intraday direction and is influenced by a combination of diverging forces. The weaker US GDP print and a rise in US inflation benefit the metal amid subdued USD demand. Hawkish Fed expectations cap the upside as traders await the release of the US PCE Price Index.
Sei Price Prediction: SEI is in the zone of interest after a 10% leap
Sei price has been in recovery mode for almost ten days now, following a fall of almost 65% beginning in mid-March. While the SEI bulls continue to show strength, the uptrend could prove premature as massive bearish sentiment hovers above the altcoin’s price.
US core PCE inflation set to signal firm price pressures as markets delay Federal Reserve rate cut bets
The core PCE Price Index, which excludes volatile food and energy prices, is seen as the more influential measure of inflation in terms of Fed positioning. The index is forecast to rise 0.3% on a monthly basis in March, matching February’s increase.